Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,521 to 1,540 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro. | FASEB J | 2021 | 34324734 | PubTator, text mining | PubMed |
| Bioinformatic analyses suggest augmented interleukin-17 signaling as the mechanism of COVID-19-associated herpes zoster. | Environ Sci Pollut Res Int | 2021 | 34322810 | PubTator, text mining | PubMed |
| SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. | Front Immunol | 2021 | 34322129 | PubTator, text mining | PubMed |
| Emergence of equine-like G3 strains as the dominant rotavirus among children under five with diarrhea in Sabah, Malaysia during 2018-2019. | PLoS One | 2021 | 34320003 | PubTator, text mining | PubMed |
| SARS-CoV-2 Antiviral Therapy. | Clin Microbiol Rev | 2021 | 34319150 | PubTator, text mining | PubMed |
| In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19. | In Silico Pharmacol | 2021 | 34312587 | PubTator, text mining | PubMed |
| Identification of Food Compounds as inhibitors of SARS-CoV-2 main protease using molecular docking and molecular dynamics simulations. | Chemometr Intell Lab Syst | 2021 | 34312571 | PubTator, text mining | PubMed |
| Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. | Biomed Pharmacother | 2021 | 34311539 | PubTator, text mining | PubMed |
| Exploiting the molecular basis of age and gender differences in outcomes of SARS-CoV-2 infections. | Comput Struct Biotechnol J | 2021 | 34306570 | PubTator, text mining | PubMed |
| Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients. | Chem Biol Interact | 2021 | 34303694 | PubTator, text mining | PubMed |
| Current Treatment of Juvenile Myelomonocytic Leukemia. | J Clin Med | 2021 | 34300250 | PubTator, text mining | PubMed |
| Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. | Int J Mol Sci | 2021 | 34299045 | PubTator, text mining | PubMed |
| Compartmentalization-aided interaction screening reveals extensive high-order complexes within the SARS-CoV-2 proteome. | Cell Rep | 2021 | 34297909 | PubTator, text mining | PubMed |
| Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV-2 replication. | Cell Biosci | 2021 | 34294141 | PubTator, text mining | PubMed |
| Reappraisal of trifluperidol against Nsp3 as a potential therapeutic for novel COVID-19: a molecular docking and dynamics study. | Future Virol | 2021 | 34290823 | PubTator, text mining | PubMed |
| Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. | Cancer Cell Int | 2021 | 34289845 | PubTator, text mining | PubMed |
| Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. | Science | 2021 | 34285133 | PubTator, text mining | PubMed |
| SARS-CoV-2: from its discovery to genome structure, transcription, and replication. | Cell Biosci | 2021 | 34281608 | PubTator, text mining | PubMed |
| Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19. | J Infect Public Health | 2021 | 34280732 | PubTator, text mining | PubMed |
| Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis. | J Genet Eng Biotechnol | 2021 | 34272647 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=77